Titanium-gold-based chemotherapeutics for prostate and kidney cancer

用于前列腺癌和肾癌的钛金化疗药物

• 批准号: 8474078
• 负责人: Maria Contel
• 金额: $ 35.33万
• 依托单位: BROOKLYN COLLEGE
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-07-01 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8474078
• 关键词: Androgens; Biochemical; Biological; Cancer Center; Cancer cell line; Carrier Proteins; Cell Death; Cisplatin; Clinical; Collaborations; Combined Modality Therapy; Complex; DNA; Data; Disease; Funding; Future; Goals; Gold; Gold Compounds; Grant; Growth; Hawaii; Health; Human; In Vitro; Institution; International; Joints; Kidney; Knowledge; Laboratories; Ligands; Malignant Neoplasms; Malignant neoplasm of ovary; Malignant neoplasm of prostate; Malignant neoplasm of testis; Measures; Metals; Mitochondrial Proteins; Molecular; Morbidity - disease rate; Organometallic Compounds; Outcome; PC3 cell line; Pathway interactions; Pharmaceutical Preparations; Pharmacologic Substance; Phosphines; Phosphotransferases; Platinum; Progression-Free Survivals; Property; Prostatic Neoplasms; Protein Kinase; Protein Kinase Inhibitors; Public Health; Renal carcinoma; Reporting; Research; Resistance; Resources; Testing; Therapeutic; Titania; Titanium; Toxic effect; Training; Universities; Woman; Work; anticancer research; base; cancer cell; cancer therapy; chemotherapy; design; experience; improved; in vivo; malignant breast neoplasm; men; mortality; pre-clinical; protein kinase inhibitor; public health relevance; tool; tumor

DESCRIPTION (provided by applicant): Kidney cancer is among the most common cancers and prostate cancer is a major cause of morbidity and mortality in men in the US. There is a clear need to increase the number of chemotherapeutic options for these cancers to use alone or in combination with targeted agents. Metallo-drugs are important tools in current cancer therapy. Platinum-derived drugs, commonly used, have failed in renal and prostate cancers. Titanium-based drugs have high preclinical activity and hold potential for anticancer therapy, especially for metastatic renal, metastatic breast and prostate cancers. However, their mode of action remains unclear. Recent studies indicate that gold complexes also display considerable anti-tumor properties both in vitro and in vivo against cisplatin-resistant cancer cell lines with different mode of action than cisplatin itself. Preliminary results demonstrate that compounds containing both titanium and gold have significant anti-tumor properties in vitro against prostate cancer cell lines. The long-term goal of this proposal is to develop heterometallic titanium-gold anticancer chemotherapeutics for the treatment of renal and prostate cancers. Our hypothesis is that the incorporation of two different metals with anti-tumor properties in the same molecule will improve their activity due to: a) interaction of the different metals with multiple biological targts and b) improved chemicophysical properties of the heterometallic compound. We will synthesize new titanium organometallic compounds with phosphine-, and iminophosphorane-modified cyclopentadienyl (Cp) ligands able to further coordinate gold moieties. The anti-tumor properties and mechanism of action of the new titanium and titanium-gold derivatives prepared will be evaluated using different human kidney and prostate cancer cell lines. Aim 1. To synthesise and to determine the stability, in vitro and in vivo anti-tumor activity of titanium and titanium-gold compounds with phosphine- and iminophosphorane-containing ligands. Aim 2: To test the hypothesis that the improved activity of titanium-gold compounds is due to their interactions with multiple biological targets. We will evaluate the interaction of these compounds with different biomolecular targets, including protein kinases, DNA, transport and mitochondrial proteins, and cell death pathways. This research will elucidate the mode of action of promising non-platinum anti-cancer heterometallic derivatives. The knowledge gained from the studies of the kinase inhibitory properties of these compounds will guide the design of more selective or targeted chemotherapeutics for treating humans in the future. We will work in collaboration with Prof. Ramos (University of Hawaii Cancer Center).

描述（由申请人提供）：肾癌是最常见的癌症之一，前列腺癌是美国男性发病率和死亡率的主要原因。显然需要增加这些癌症单独使用或与靶向药物联合使用的化疗选择的数量。金属药物是目前癌症治疗的重要工具。常用的铂衍生药物在肾癌和前列腺癌中失败了。钛基药物具有很高的临床前活性，并具有抗癌治疗的潜力，特别是对于转移性肾癌、转移性乳腺癌和前列腺癌。然而，它们的作用方式仍不清楚。最近的研究表明，金配合物也显示出相当大的抗肿瘤特性，在体外和体内对顺铂耐药的癌细胞系与不同的模式的行动比顺铂本身。初步结果表明，含有钛和金的化合物在体外对前列腺癌细胞系具有显着的抗肿瘤特性。该提案的长期目标是开发用于治疗肾癌和前列腺癌的异金属钛金抗癌化疗药物。我们的假设是，在同一分子中掺入两种具有抗肿瘤特性的不同金属， 改善他们的活动，因为：a）不同金属与多种生物靶标的相互作用和B）改进的异金属化合物的化学物理性质。我们将合成新的钛金属有机化合物与膦，和亚氨基磷烷改性的双（Cp）配体能够进一步协调金部分。将使用不同的人肾癌和前列腺癌细胞系评价制备的新钛和钛-金衍生物的抗肿瘤特性和作用机制。目标1.合成并测定含膦和亚氨基膦配体的钛和钛-金化合物的稳定性、体外和体内抗肿瘤活性。目的2：验证钛-金化合物的活性提高是由于它们与多个生物靶标相互作用的假设。我们将评估这些化合物与不同生物分子靶点的相互作用，包括蛋白激酶、DNA、转运和线粒体蛋白以及细胞死亡途径。本研究将阐明有前途的非铂类抗癌异金属衍生物的作用方式。从这些化合物的激酶抑制特性的研究中获得的知识将指导未来用于治疗人类的更具选择性或靶向的化疗药物的设计。我们将与拉莫斯教授（夏威夷大学癌症中心）合作。